

**Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: *in vitro* cell-based anticancer studies**

Avik Maji<sup>a</sup>, Ambati Himaja<sup>b</sup>, Sripathi Nikhitha<sup>b</sup>, Soumitra Rana<sup>c</sup>, Abhik Paul<sup>a</sup>, Ajeya Samanta<sup>a</sup>, Uday Shee<sup>d</sup>, Chhanda Mukhopadhyay<sup>c</sup>, Balaram Ghosh<sup>b\*</sup>, Tapan Kumar Maity<sup>a\*</sup>

<sup>a</sup> Synthetic and Natural Products Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata-700032, West Bengal, India

<sup>b</sup> Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Hyderabad-500078, India

<sup>c</sup> Department of Chemistry, University of Calcutta, Kolkata - 700009, West Bengal, India

<sup>d</sup> Department of Chemistry, Jadavpur University, Kolkata - 700032, West Bengal, India

**\*Corresponding authors:**

**Prof. (Dr.) Tapan Kumar Maity**

Synthetic and Natural Products Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata-700032, India.

**Orchid:** <https://orcid.org/0000-0002-3245-7297>

**E-mail:** [tapan.maity@jadavpuruniversity.in](mailto:tapan.maity@jadavpuruniversity.in)

**Prof. (Dr.) Balaram Ghosh**

Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Hyderabad-500078, India.

**Orchid:** <https://orcid.org/0000-0002-3425-2439>

**E-mail:** [balaram@hyderabad.bits-pilani.ac.in](mailto:balaram@hyderabad.bits-pilani.ac.in)

## **CONTENTS:**

<b>Copy of Spectral data.</b>	<b><u>Pages</u></b>
1. $^1\text{H}$ NMR, $^{13}\text{C}$ NMR and $^{19}\text{F}$ NMR data.....	S3-S39
2. HRMS data for the final compounds.....	S40-S43

## **X-Ray Crystallographic data:**


1. Molecular geometry of compounds **6g** and **7f** ..... S44
2. Tabular data of crystal..... S45

## **Biological assay data:**


1. Dose-response curve of compounds series (**5a-g**, **6a-g** and **7a-g**) on various cancer cell lines generated via MTT assay..... S46


**Copy of  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{19}\text{F}$  NMR data:**

Compd 1




1







2




2b




2b




2c




2c



3a




3a





3b


S.F6': <sup>1</sup>H NMR of compound 3b

3b


S.F6'': <sup>13</sup>C NMR of compound 3b




4a




4A




4b




4b




4c




4c




5A




5A




5b






5b



5b









S.F13'''': <sup>19</sup>F NMR of compound 5c


5D




5D







5E




5E




S.F16': <sup>1</sup>H NMR of compound 5fS.F16'': <sup>13</sup>C NMR of compound 5f







6A



6b





6b




6B

-111.603




S.F19'''': <sup>19</sup>F NMR of compound 6b

6c





6c




6C

—108.490






S.F20'''': <sup>19</sup>F NMR of compound 6c



6D




6D



S.F22': <sup>1</sup>H NMR of compound 6eS.F22'': <sup>13</sup>C NMR of compound 6e




6g




S.F24': <sup>1</sup>H NMR of compound 6g

6g




S.F24'': <sup>13</sup>C NMR of compound 6g


7A




7a




7b




7B



7B




7c



S.F27': <sup>1</sup>H NMR of compound 7c



7c



S.F27'': <sup>13</sup>C NMR of compound 7c


7c

—108.458




S.F27'''': <sup>19</sup>F NMR of compound 7c


7d




7d




7E

S.F29': <sup>1</sup>H NMR of compound 7e


7E

S.F29'': <sup>13</sup>C NMR of compound 7e


7F




7F




7g




7g




## Copy of HRMS Data (Final Compounds):




S.F32: HRMS Compound 5a




S.F33: HRMS Compound 5b




S.F34: HRMS Compound 5c




S.F35: HRMS Compound 5d




**S.F36: HRMS Compound 6a**




**S.F37: HRMS Compound 6b**




**S.F38: HRMS Compound 6c**




**S.F39: HRMS Compound 6d**




**S.F40: HRMS Compound 6e**




**S.F41: HRMS Compound 6f**




**S.F42: HRMS Compound 7a**






**S.F43: HRMS Compound 7b**




**S.F44: HRMS Compound 7c**



**S.F45: HRMS Compound 7d**



**X-Ray Crystallography of compounds 6g and 7f:**




**S.F49:** Molecular geometries of (a) **6g** and (b) **7f** in crystals.

**Table S1: Crystallographic table:**

Complexes	6g	7f
CCDC	2366716	2366780
formula	C <sub>20</sub> H <sub>15</sub> ClN <sub>4</sub> O <sub>3</sub> S <sub>3</sub>	C <sub>19</sub> H <sub>12</sub> Cl <sub>2</sub> N <sub>4</sub> O <sub>2</sub> S <sub>3</sub>
fw	490.99	495.41
crystal system	triclinic	monoclinic
space group	P -1	P 21/c
<i>a</i> (Å)	10.270(2)	10.146(2)
<i>b</i> (Å)	10.497(2)	17.022(5)
<i>c</i> (Å)	13.887(3)	15.237(4)
$\alpha$ (°)	73.266(7)	90
$\beta$ (°)	81.446(7)	101.398(7)
$\gamma$ (°)	85.763(6)	90
<i>V</i> (Å <sup>3</sup> )	1416.8(5)	2579.5(11)
<i>Z</i>	2	4
<i>T</i> (K)	299	299
Dx, g cm <sup>-3</sup>	1.275	1.477
$\mu$ (mm <sup>-1</sup> )	0.389	0.607
R1 <sup>a</sup> [I>2σ(I)]/GOF <sup>b</sup>	0.0514/ 1.020	0.0580/ 1.026
wR2 <sup>c</sup> (I>2σ (I))	0.1689	0.1938
observation criterion: <sup>a</sup> R1 = $\sum   F_o  -  F_c   / \sum  F_o $ . <sup>b</sup> GOF = $\{\sum [w(F_o^2 - F_c^2)^2] / (n-p)\}^{1/2}$ , <sup>c</sup> wR2 = $[\sum [w(F_o^2 - F_c^2)^2] / \sum [w(F_o^2)^2]]^{1/2}$ where w = 1/[σ <sup>2</sup> (F <sub>o</sub> <sup>2</sup> ) + (aP) <sup>2</sup> +bP], P = (F <sub>o</sub> <sup>2</sup> +2F <sub>c</sub> <sup>2</sup> )/3.		

## Biological assay data:



**S.F50:** Dose-response curve and IC<sub>50</sub> values of **5a-g**, **6a-g**, and **7a-g** series of compounds along with **BG45**. All compounds were tested in the concentrations range of 0.195 μM - 200 μM on (A) MCF-7, (B) PC3, (C) 4T1, (D) MOC2, (E) MDA-MB-231, and (F) HEK-293. Cells were treated with compounds for 48 h, and cell viability was measured using the *in vitro* MTT assay method. Data represents mean ± SD (n = 2) and is plotted in dose-response format. IC<sub>50</sub> was calculated using a nonlinear regression analysis method using GraphPad Prism 8.0.1.

**NB. S. F:** Supplementary Figure